The United States Patent and Trademark Office (USPTO) has issued patent US12583891B2, granting exclusive rights to PHOENIX ALPHA for peptides, specifically citing HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26], and their methods of use in treating type 1 diabetes. The patent also covers the generation of cytolytic CD4+ T cells as part of the treatment process. This grant is based on an application filed on August 8, 2023, and includes 11 claims.

This patent grant signifies a new intellectual property right for a specific therapeutic approach to type 1 diabetes. While not a regulatory mandate for other entities, it establishes exclusive rights for the assignee, PHOENIX ALPHA, in the development and commercialization of these peptides for this indication. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in diabetes research or peptide therapeutics, should be aware of this patent to avoid potential infringement and to inform their own R&D strategies.